A Phase 1 study evaluated the pharmacokinetics, safety and tolerability of two intramuscular single-dose 5000mg lenacapavir formulations
Latest Information Update: 21 Mar 2025
At a glance
- Drugs Lenacapavir (Primary)
- Indications HIV infections
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 21 Mar 2025 New trial record
- 11 Mar 2025 According to a Gilead Sciences Media Release, data from this study were presented in a oral abstract session at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) and were also published in The Lancet.
- 11 Mar 2025 Results presented in the Gilead Sciences Media Release.